As Washington ramps up efforts to tighten cross-border life sciences deals involving Chinese assets, Beijing is moving to ...

Frazier Life Sciences also hit the Nasdaq on Friday with its second biotech-focused special purpose acquisition company (SPAC ...

Estuary Biotherapeutics has swum out of stealth with $103 million in funding to power a pair of gene therapies into clinical ...

When Fierce last caught up with OMass Therapeutics’ CEO Ros Deegan, it was hard not to be impressed by the company’s ambition ...

As the world's biggest biotech hub, funding for early-stage startups has long been the lifeblood of Boston's life sciences ...

Labcorp has launched the Thrive 5 Health Test that is now offered through a collaboration with Arianna Huffington's behavior ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Iambic Therapeutics’ IPO came in dead on target, bringing in $150 million for the AI biotech to fuel the clinical development ...

AstraZeneca is paying insitro $40 million upfront to find novel drug targets for liver and heart diseases using artificial ...

Verastem Oncology's decision to refocus its R&D efforts on its KRAS inhibitor appears to be paying off, at least based on ...

Lakefront Biotherapeutics—the new name for Belgium’s Galapagos Therapeutics—has found a buyer for its unwanted cell therapy ...

Osivax has been forced to alter the strategy for its influenza vaccine after the shot failed a phase 2b study. France’s ...